Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade.

Shekarian T, Sivado E, Jallas AC, Depil S, Kielbassa J, Janoueix-Lerosey I, Hutter G, Goutagny N, Bergeron C, Viari A, Valsesia-Wittmann S, Caux C, Marabelle A.

Sci Transl Med. 2019 Oct 23;11(515). pii: eaat5025. doi: 10.1126/scitranslmed.aat5025.

PMID:
31645452
2.

Immunoengineering in glioblastoma imaging and therapy.

Zanganeh S, Georgala P, Corbo C, Arabi L, Ho JQ, Javdani N, Sepand MR, Cruickshank K, Campesato LF, Weng CH, Hemayat S, Andreou C, Alvim R, Hutter G, Rafat M, Mahmoudi M.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Nov;11(6):e1575. doi: 10.1002/wnan.1575. Epub 2019 Aug 12. Review.

PMID:
31407522
3.

Quantitative proteomics reveals reduction of endocytic machinery components in gliomas.

Buser DP, Ritz MF, Moes S, Tostado C, Frank S, Spiess M, Mariani L, Jenö P, Boulay JL, Hutter G.

EBioMedicine. 2019 Aug;46:32-41. doi: 10.1016/j.ebiom.2019.07.039. Epub 2019 Jul 19.

4.

Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma.

Hutter G, Theruvath J, Graef CM, Zhang M, Schoen MK, Manz EM, Bennett ML, Olson A, Azad TD, Sinha R, Chan C, Assad Kahn S, Gholamin S, Wilson C, Grant G, He J, Weissman IL, Mitra SS, Cheshier SH.

Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):997-1006. doi: 10.1073/pnas.1721434116. Epub 2019 Jan 2.

5.

Publisher Correction: Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma.

Kahn SA, Wang X, Nitta RT, Gholamin S, Theruvath J, Hutter G, Azad TD, Wadi L, Bolin S, Ramaswamy V, Esparza R, Liu KW, Edwards M, Swartling FJ, Sahoo D, Li G, Wechsler-Reya RJ, Reimand J, Cho YJ, Taylor MD, Weissman IL, Mitra SS, Cheshier SH.

Nat Commun. 2018 Nov 2;9(1):4651. doi: 10.1038/s41467-018-07182-1.

6.

Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma.

Kahn SA, Wang X, Nitta RT, Gholamin S, Theruvath J, Hutter G, Azad TD, Wadi L, Bolin S, Ramaswamy V, Esparza R, Liu KW, Edwards M, Swartling FJ, Sahoo D, Li G, Wechsler-Reya RJ, Reimand J, Cho YJ, Taylor MD, Weissman IL, Mitra SS, Cheshier SH.

Nat Commun. 2018 Oct 8;9(1):4121. doi: 10.1038/s41467-018-06564-9. Erratum in: Nat Commun. 2018 Nov 2;9(1):4651.

7.

[The cure of Timothy Brown. How is his condition now and has this case been repeated?]

Hütter G.

MMW Fortschr Med. 2018 Jun;160(Suppl 2):27-30. doi: 10.1007/s15006-018-0651-5. Review. German. No abstract available.

PMID:
29943332
8.

Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.

Teipel R, Oelschlägel U, Wetzko K, Schmiedgen M, Kramer M, Rücker-Braun E, Hölig K, von Bonin M, Heidrich K, Fuchs A, Ordemann R, Kroschinsky F, Bornhäuser M, Hütter G, Schmidt H, Ehninger G, Schetelig J, Heidenreich F.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2171-2177. doi: 10.1016/j.bbmt.2018.06.023. Epub 2018 Jun 21.

9.

Transient antagonism of anti-CD20 monoclonal antibodies and PI3K inhibitor idelalisib in DLBCL cell lines.

Zoellner AK, Peter N, Zimmermann Y, Hutter G, Hiddemann W, Dreyling M.

Eur J Haematol. 2018 Apr 4. doi: 10.1111/ejh.13075. [Epub ahead of print]

PMID:
29617050
10.

Single-Stage Preparation of Human Cartilage Grafts Generated from Bone Marrow-Derived CD271+ Mononuclear Cells.

Petters O, Schmidt C, Henkelmann R, Pieroh P, Hütter G, Marquass B, Aust G, Schulz RM.

Stem Cells Dev. 2018 Apr 15;27(8):545-555. doi: 10.1089/scd.2017.0218.

PMID:
29482445
11.

Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.

Zanganeh S, Spitler R, Hutter G, Ho JQ, Pauliah M, Mahmoudi M.

Immunotherapy. 2017 Sep;9(10):819-835. doi: 10.2217/imt-2017-0041. Review.

PMID:
28877626
12.

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL.

Nature. 2017 May 25;545(7655):495-499. doi: 10.1038/nature22396. Epub 2017 May 17.

13.

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.

Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, Volkmer AK, Willingham S, Ponnuswami A, McCarty A, Lovelace P, Storm TA, Schubert S, Hutter G, Narayanan C, Chu P, Raabe EH, Harsh G 4th, Taylor MD, Monje M, Cho YJ, Majeti R, Volkmer JP, Fisher PG, Grant G, Steinberg GK, Vogel H, Edwards M, Weissman IL, Cheshier SH.

Sci Transl Med. 2017 Mar 15;9(381). pii: eaaf2968. doi: 10.1126/scitranslmed.aaf2968.

PMID:
28298418
14.

Reverse phase protein arrays enable glioblastoma molecular subtyping.

Hutter G, Sailer M, Azad TD, von Bueren AO, Nollau P, Frank S, Tostado C, Sarvepalli D, Ghosh A, Ritz MF, Boulay JL, Mariani L.

J Neurooncol. 2017 Feb;131(3):437-448. doi: 10.1007/s11060-016-2316-5. Epub 2016 Nov 17.

PMID:
27858266
15.

Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues.

Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, Pajarinen JS, Nejadnik H, Goodman S, Moseley M, Coussens LM, Daldrup-Link HE.

Nat Nanotechnol. 2016 Nov;11(11):986-994. doi: 10.1038/nnano.2016.168. Epub 2016 Sep 26.

16.

Stem cell transplantation in strategies for curing HIV/AIDS.

Hütter G.

AIDS Res Ther. 2016 Sep 13;13(1):31. doi: 10.1186/s12981-016-0114-y. eCollection 2016. Review.

17.

An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery.

Sailer MH, Sarvepalli D, Brégère C, Fisch U, Guentchev M, Weller M, Guzman R, Bettler B, Ghosh A, Hutter G.

J Vis Exp. 2016 Aug 23;(114). doi: 10.3791/54018.

18.

HIV+ patients and HIV eradication - allogeneic transplantation.

Hütter G.

Expert Rev Hematol. 2016 Jul;9(7):615-6. doi: 10.1080/17474086.2016.1183478. Epub 2016 May 10. No abstract available.

PMID:
27139903
19.

Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.

Zhang M, Hutter G, Kahn SA, Azad TD, Gholamin S, Xu CY, Liu J, Achrol AS, Richard C, Sommerkamp P, Schoen MK, McCracken MN, Majeti R, Weissman I, Mitra SS, Cheshier SH.

PLoS One. 2016 Apr 19;11(4):e0153550. doi: 10.1371/journal.pone.0153550. eCollection 2016.

20.

The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.

Seiler T, Hutter G, Dreyling M.

Drugs. 2016 Apr;76(6):639-46. doi: 10.1007/s40265-016-0565-4. Review.

PMID:
27052260
21.

Temsirolimus acts as additive with bendamustine in aggressive lymphoma.

Zoellner AK, Weiglein T, Hutter G, Zimmermann Y, Cieplik HC, Hess G, Dreyling M.

Ann Hematol. 2016 Feb;95(3):403-7. doi: 10.1007/s00277-015-2570-1. Epub 2015 Dec 11.

PMID:
26658770
22.

Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway.

Zoellner AK, Bayerl S, Hutter G, Zimmermann Y, Hiddemann W, Dreyling M.

Leuk Lymphoma. 2015;56(12):3393-400. doi: 10.3109/10428194.2015.1023720. Epub 2015 Aug 3.

PMID:
26237681
23.

Intracranial Interdigitating Dendritic Cell Sarcoma: First Case Report.

Hutter G, Hofer S, Tzankov A, Kothbauer KF.

Neurosurgery. 2015 Dec;77(6):E979-83. doi: 10.1227/NEU.0000000000000925.

PMID:
26237342
24.

CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape.

Hütter G, Bodor J, Ledger S, Boyd M, Millington M, Tsie M, Symonds G.

Viruses. 2015 Jul 27;7(8):4186-203. doi: 10.3390/v7082816. Review.

25.

Neural Placode Tissue Derived From Myelomeningocele Repair Serves as a Viable Source of Oligodendrocyte Progenitor Cells.

Mitra SS, Feroze AH, Gholamin S, Richard C, Esparza R, Zhang M, Azad TD, Alrfaei B, Kahn SA, Hutter G, Guzman R, Creasey GH, Plant GW, Weissman IL, Edwards MS, Cheshier S.

Neurosurgery. 2015 Nov;77(5):794-802; discussion 802. doi: 10.1227/NEU.0000000000000918.

PMID:
26225855
26.

Machinery Safety Survey Results: Safety Interlocks and Used Equipment.

Hutter GM.

Occup Health Saf. 2015 Mar;84(3):56-8. No abstract available.

PMID:
26204625
27.

Distribution of the CCR5-delta32 deletion in Southwest Germany.

Hütter G, Blüthgen C, Elvers-Hornung S, Klüter H, Bugert P.

Anthropol Anz. 2015;72(3):303-9. doi: 10.1127/anthranz/2015/0479. Epub 2015 Feb 3.

PMID:
25807520
28.

[Bouveret syndrome. What is obstructing the duodenum?].

Hütter G.

MMW Fortschr Med. 2015 Feb 5;157(2):5. German. No abstract available.

PMID:
25743492
29.

More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation.

Hütter G.

N Engl J Med. 2014 Dec 18;371(25):2437-8. doi: 10.1056/NEJMc1412279. No abstract available.

PMID:
25517721
30.

Regenerating blood: towards engineering HIV-1-resistant hematopoietic stem cells.

Hütter G.

Regen Med. 2014;9(6):705-7. doi: 10.2217/rme.14.62. No abstract available.

31.

Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.

Heinrich DA, Weinkauf M, Hutter G, Zimmermann Y, Jurinovic V, Hiddemann W, Dreyling M.

Br J Haematol. 2015 Feb;168(4):606-10. doi: 10.1111/bjh.13132. Epub 2014 Oct 8. No abstract available.

PMID:
25292485
32.

Risk factors for postoperative CSF leakage after elective craniotomy and the efficacy of fleece-bound tissue sealing against dural suturing alone: a randomized controlled trial.

Hutter G, von Felten S, Sailer MH, Schulz M, Mariani L.

J Neurosurg. 2014 Sep;121(3):735-44. doi: 10.3171/2014.6.JNS131917. Epub 2014 Jul 18.

PMID:
25036199
33.

Dependence on the CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient.

Symons J, Vandekerckhove L, Hütter G, Wensing AM, van Ham PM, Deeks SG, Nijhuis M.

Clin Infect Dis. 2014 Aug 15;59(4):596-600. doi: 10.1093/cid/ciu284. Epub 2014 Apr 23.

34.

Expression of different neurokinin-1 receptor (NK1R) isoforms in glioblastoma multiforme: potential implications for targeted therapy.

Cordier D, Gerber A, Kluba C, Bauman A, Hutter G, Mindt TL, Mariani L.

Cancer Biother Radiopharm. 2014 Jun;29(5):221-6. doi: 10.1089/cbr.2013.1588. Epub 2014 Feb 19.

PMID:
24552486
35.

CCR5 as a natural and modulated target for inhibition of HIV.

Burke BP, Boyd MP, Impey H, Breton LR, Bartlett JS, Symonds GP, Hütter G.

Viruses. 2013 Dec 30;6(1):54-68. doi: 10.3390/v6010054.

36.

HIV antibody characterization as a method to quantify reservoir size during curative interventions.

Burbelo PD, Bayat A, Rhodes CS, Hoh R, Martin JN, Fromentin R, Chomont N, Hütter G, Kovacs JA, Deeks SG.

J Infect Dis. 2014 May 15;209(10):1613-7. doi: 10.1093/infdis/jit667. Epub 2013 Nov 28.

37.

Coregulation of HIV-1 dependency factors in individuals heterozygous to the CCR5-delta32 deletion.

Hütter G, Blüthgen C, Neumann M, Reinwald M, Nowak D, Klüter H.

AIDS Res Ther. 2013 Nov 18;10(1):26. doi: 10.1186/1742-6405-10-26.

38.

SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells.

Nuvolone M, Kana V, Hutter G, Sakata D, Mortin-Toth SM, Russo G, Danska JS, Aguzzi A.

J Exp Med. 2013 Nov 18;210(12):2539-52. doi: 10.1084/jem.20131274. Epub 2013 Oct 21.

39.

[History of the "Berlin patient" and the promise of a zinc-finger based HIV gene therapy].

Hütter G.

MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:17, 19. German. No abstract available.

PMID:
23961646
40.

Non-invasive neural stem cells become invasive in vitro by combined FGF2 and BMP4 signaling.

Sailer MH, Gerber A, Tostado C, Hutter G, Cordier D, Mariani L, Ritz MF.

J Cell Sci. 2013 Aug 15;126(Pt 16):3533-40. doi: 10.1242/jcs.125757. Epub 2013 Jun 20.

41.

Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.

Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, Eisele E, Haase A, Ho YC, Hütter G, Justement JS, Keating S, Lee TH, Li P, Murray D, Palmer S, Pilcher C, Pillai S, Price RW, Rothenberger M, Schacker T, Siliciano J, Siliciano R, Sinclair E, Strain M, Wong J, Richman D, Deeks SG.

PLoS Pathog. 2013;9(5):e1003347. doi: 10.1371/journal.ppat.1003347. Epub 2013 May 9.

42.

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.

Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E, Schulz M, Hutter G, Hench J, Schucht P, Boulay JL, Mariani L.

Neuro Oncol. 2013 Apr;15(4):469-79. doi: 10.1093/neuonc/nos317. Epub 2013 Feb 13.

43.

Skewed X-inactivation patterns in ageing healthy and myelodysplastic haematopoiesis determined by a pyrosequencing based transcriptional clonality assay.

Mossner M, Nolte F, Hütter G, Reins J, Klaumünzer M, Nowak V, Obländer J, Ackermann K, Will S, Röhl H, Neumann U, Neumann M, Hopfer O, Baldus CD, Hofmann WK, Nowak D.

J Med Genet. 2013 Feb;50(2):108-17. doi: 10.1136/jmedgenet-2012-101093.

PMID:
23339109
44.

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.

Dreyling M, Kluin-Nelemans HC, Beà S, Klapper W, Vogt N, Delfau-Larue MH, Hutter G, Cheah C, Chiappella A, Cortelazzo S, Pott C, Hess G, Visco C, Vitolo U, Klener P, Aurer I, Unterhalt M, Ribrag V, Hoster E, Hermine O; European MCL Network.

Leuk Lymphoma. 2013 Apr;54(4):699-707. doi: 10.3109/10428194.2012.733882. Epub 2012 Nov 21. Review.

PMID:
23020649
45.

Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL.

Hutter G, Zimmermann Y, Rieken M, Hartmann E, Rosenwald A, Hiddemann W, Dreyling M.

Leukemia. 2012 Nov;26(11):2442-4. doi: 10.1038/leu.2012.118. Epub 2012 May 3. No abstract available.

PMID:
22552006
46.

SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.

Nowak D, Klaumuenzer M, Hanfstein B, Mossner M, Nolte F, Nowak V, Oblaender J, Hecht A, Hütter G, Ogawa S, Kohlmann A, Haferlach C, Schlegelberger B, Braess J, Seifarth W, Fabarius A, Erben P, Saussele S, Müller MC, Reiter A, Buechner T, Weiss C, Hofmann WK, Lengfelder E.

Genes Chromosomes Cancer. 2012 Aug;51(8):756-67. doi: 10.1002/gcc.21961. Epub 2012 Apr 9.

PMID:
22488577
47.

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.

Hutter G, Rieken M, Pastore A, Weigert O, Zimmermann Y, Weinkauf M, Hiddemann W, Dreyling M.

Ann Hematol. 2012 Jun;91(6):847-56. doi: 10.1007/s00277-011-1377-y. Epub 2012 Jan 11.

PMID:
22231280
48.

The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation.

Hütter G, Neumann M, Nowak D, Klein S, Klüter H, Hofmann WK.

J Inflamm (Lond). 2011 Oct 26;8:29. doi: 10.1186/1476-9255-8-29.

49.

Medical importance of Sindbis virus in south-west Germany.

Jöst H, Bürck-Kammerer S, Hütter G, Lattwein E, Lederer S, Litzba N, Bock-Hensley O, Emmerich P, Günther S, Becker N, Niedrig M, Schmidt-Chanasit J.

J Clin Virol. 2011 Nov;52(3):278-9. doi: 10.1016/j.jcv.2011.08.002. Epub 2011 Sep 3. No abstract available.

PMID:
21893428
50.

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.

Dreyling M, Kluin-Nelemans HC, Beà S, Hartmann E, Salaverria I, Hutter G, Perez-Galan P, Roue G, Pott C, Le Gouill S, Cortelazzo S, Rule S, Hess G, Zaja F, Vitolo U, Szymczyk M, Walewski J, Ribrag V, Unterhalt M, Hermine O, Hoster E; European Mantle Cell Lymphoma Network.

Leuk Lymphoma. 2011 Dec;52(12):2226-36. doi: 10.3109/10428194.2011.600488. Epub 2011 Aug 18. Review.

PMID:
21851218

Supplemental Content

Loading ...
Support Center